AUTHORS
Yue Shang, Yanping Zeng2, yajuan liu3, Jiesi Li4, Jinsong He5, Lingna Li6, Zheng Tian7, Min Wang, PhD8, Jianxiang Wang Sr, MD, PhD9, Zhangsong Yan10, Yingchang Mi, MD11
AFFILIATIONS
1 National Clinical Research Center for Blood Diseases. State Key Laboratory of Experimental Hematology. Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, China
2 National Clinical Research Center for Blood Diseases. State Key Laboratory of Experimental Hematology. Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, China
3 National Clinical Research Center for Blood Diseases. State Key Laboratory of Experimental Hematology. Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, China
4 National Clinical Research Center for Blood Diseases. State Key Laboratory of Experimental Hematology. Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, China
5 National Clinical Research Center for Blood Diseases. State Key Laboratory of Experimental Hematology. Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, China
6 National Clinical Research Center for Blood Diseases. State Key Laboratory of Experimental Hematology. Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, China
7 National Clinical Research Center for Blood Diseases. State Key Laboratory of Experimental Hematology. Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, China
8 National Clinical Research Center for Blood Diseases. State Key Laboratory of Experimental Hematology. Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, China
9 National Clinical Research Center for Blood Diseases. State Key Laboratory of Experimental Hematology. Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, China
10 National Clinical Research Center for Blood Diseases. State Key Laboratory of Experimental Hematology. Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, China
11 National Clinical Research Center for Blood Diseases. State Key Laboratory of Experimental Hematology. Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, China
ABSTRACT
Background
Venetoclax (VEN)-based regimens have improved response rates in acute myeloid leukemia (AML), but their impact on post-remission hematopoietic recovery remains incompletely characterized. We evaluated the clinical activity of homoharringtonine, cytarabine, and venetoclax (HAV) induction, followed by sequence-adapted cytarabine-based consolidation with or without VEN.
Methods
Patients with AML treated with HAV induction between November 2024 and December 2025 were analyzed. Treatment response was classified according to ELN 2022 criteria. Patients proceeding to consolidation were grouped by treatment sequence: group A received intermediate-dose cytarabine (ID-AraC) followed by ID-AraC plus VEN, whereas group B received ID-AraC plus VEN followed by ID-AraC. Clinical responses, hematologic recovery, infection events and hospitalization duration, flow-cytometric recovery of normal marrow populations, colony-forming capacity, and ex vivo VEN effects on remission bone marrow mononuclear cells (BMNCs) were assessed. All P values were two-sided and unadjusted for multiple comparisons.
Results
Thirty-five patients received HAV induction. Median age was 40 years (IQR, 34–50), and 18 patients were male. ELN 2022 risk was favorable, intermediate, and adverse in 14, 13, and 8 patients, respectively. Thirty-three patients were evaluable for induction response. According to ELN 2022 criteria, 26/33 patients (78.8%) achieved complete remission (CR), 1/33 (3.0%) achieved partial remission, yielding an overall response rate of 81.8%. Two additional patients achieved marrow remission with persistent central nervous system leukemia, yielding a marrow response rate of 87.9%. Postinduction marrow measurable residual disease (MRD) negativity was documented in 25/33 patients (75.8%).
Among patients who completed both consolidation courses (group A, n=12; group B, n=10), infection incidence and hospitalization duration did not differ significantly between groups. In available-case analyses (group A, n=10; group B, n=6–9, depending on the endpoint and course), no significant between-group differences were observed in the durations of PLT <25 × 10^9/L, HGB <65 g/L, or ANC <0.5 × 10^9/L during either consolidation course (all P>0.100). Despite comparable peripheral blood recovery, a patient- and period-adjusted crossover analysis of flow-cytometric data (43 observations from 22 patients) showed that VEN-containing consolidation was associated with a lower proportion of normal myeloid progenitor/blast-like cells (estimate, −0.265 percentage points; P=0.014), whereas the B-cell and monocyte compartments were not significantly altered.
After consolidation 1 (group A, n=8; group B, n=8), CFU-GEMM output was higher in group A than in group B (median, 6.3 vs 3.2; P=0.026). After consolidation 2 (group A, n=7; group B, n=8), group B showed higher CFU-GM output than group A (median, 49.00 vs 25.33; P=0.002) and higher total colony output per 10^4 cells (27.83 vs 17.27; P=0.003). BFU-E (48.33 vs 27.33; P=0.054) and CFU-GEMM output (4.17 vs 1.67; P=0.058) were numerically higher in group B but did not reach statistical significance. Within group B (paired n=8), total colony output increased from consolidation 1 to consolidation 2 (17.93 vs 27.83; P=0.016).
In ex vivo assays using remission BMNCs, 24-hour VEN exposure increased total apoptosis compared with DMSO, from 10.15% (IQR, 4.17–18.80) to 16.98% (IQR, 6.27–25.23; n=15; P<0.001). After 24-hour treatment, BMNCs were recounted, and equal numbers of viable cells were plated for colony assays. In three independent samples, each tested in technical triplicate, VEN reduced total colony output compared with DMSO, with each within-sample comparison yielding P<0.05.
Conclusions
HAV induction demonstrated encouraging early antileukemic activity in this AML cohort, with high response and marrow MRD-negative rates. Although VEN exposure had measurable effects on the proportion of normal myeloid progenitor/blast-like cells, BMNC apoptosis, and colony-forming capacity, short-term VEN-containing consolidation did not compromise overall hematopoietic recovery, as reflected by peripheral blood recovery. These findings support further evaluation and optimization of VEN-containing consolidation strategies in AML.
DISCLOSURES
Yue Shang: No relevant conflicts of interest to declare.